This article was originally published in Start Up
Executive SummaryMid-stage clinical trial data rarely provide an easy answer on whether to advance a compound into complex and costly pivotal studies. Agilix Corp. has stepped into that void to offer gene expression analysis services using its GenCompass-a microarry-based expression profiling system that provides a rapid whole genome comparison between test and control subjects, providing data even about as yet uncharacterized genes.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.